1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tumor cell-intrinsic activity of the RNA receptor RIG-I promotes checkpoint inhibitor-mediated anticancer immunity
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Bek, S.; Steiger, K.; Winter, C.; Rad, R.; van den Brink, M. R. M.; Ruland, J.; Bassermann, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT
    Meeting Abstract

    Vogel, A.; Kudo, M.; Cheng, A. L.; Sung, M. W.; Finn, R. S.; Lin, A. Y.; Abou-Alfa, G. K.; Alsina, A.; Breder, V.; Tebbutt, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Ibrutinib treatment in Waldenström's macroglobulinemia (WM): Follow-up results of the phase 3 iNNOVATE™ study
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; Garcia-Sanz, R.; Macdonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Geißler, M.; Nguyen, L. T.; Chapel, S.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Abou-Alfa, G. K.; Lacy, S.
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    von Amsberg, G.; Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; van der Heijden, M. S.; Shen, X.; Ding, B.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • CheckMate 214 patients who discontinued first-line nivolumab + ipilimumab or sunitinib due to treatment-related adverse events
    Meeting Abstract

    Grünwald, V.; Tannir, N. M.; Motzer, R. J.; Plimack, E. R.; McDermott, D. F.; Barthélémy, P.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Grüllich, C.; Rini, B. I.; Huseni, M.; Atkins, M.; McDermott, D.; Powles, T.; Escudier, B.; Banchereau, R.; Liu, L. F.; Leng, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Long-term survival outcomes with nivolumab (NIVO) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response
    Meeting Abstract

    Wohlleber, M.; Brahmer, J.; Borghaei, H.; Ramalingam, S. S.; Horn, L.; Carpeño, J. D.; Pluzanski, A.; Burgio, M. A.; Garassino, M.; Chow, L. Q. M.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save